Alerta

方法及びマイクロバイオーム組成物の使用

Resumen de: US2022082552A1

0001 Methods and uses of compositions (e.g. comprising one or more microbial strains) are disclosed.

METHODS FOR PREDICTING RISK FOR INFLAMMATION

Resumen de: EP4826385A1

The present invention relates to method of determining risk of an inflammatory condition, and/or risk of progression of an inflammatory condition, as well as to compounds for use in these methods.

バイオマーカー及び生体分子をタグ付けするのに有用な芳香族アルキン化合物

Resumen de: WO2025062119A2

The invention relates to a compound of formula I, wherein: A, B, R1, R2, L1, m and n are as defined in the specification, or a salt or solvate thereof, which compounds are useful for forming Raman-tagged bioconjugates with a biomarker and/or biomolecule and are detectable with Raman spectroscopy

間質性肺疾患の処置のためのバイオマーカー

Resumen de: WO2022182949A2

The present disclosure provides biomarkers associated with caveolin-1 peptide therapy in subjects with interstitial lung disease. In particular, the present disclosure describes biomarkers such as MYDGF, soluble RAGE, pSMAD2/3, and PDGFRβ associated with caveolin-1 peptide therapy in subjects with idiopathic pulmonary fibrosis. These biomarkers could be used to determine efficacy, monitoring, and optimal dosing of caveolin-1 peptide therapy in subjects with interstitial lung disease.

脳内リン恒常性促進剤に基づく治療法

Resumen de: WO2025016362A1

The present invention relates to the field of biomedicine, in particular, to the use of an intracerebral phosphate homeostasis promoter in cerebral calcification diseases. The intracerebral phosphate homeostasis promoter comprises an agent capable of regulating alternative splicing in an intron of the SLC20A2 gene or an agent targeting astrocytes. In addition, further provided in the present invention are an agent capable of regulating alternative splicing in an intron of the SLC20A2 gene, and the use thereof. Further provided in the present invention are a cerebral calcification model based on alternative splicing in an intron of the human SLC20A2 gene, and a preparation method therefor and the use thereof.

筛选野生型α-突触核蛋白聚集抑制剂和纤维解聚剂的方法和试剂盒及其应用

Resumen de: CN122922424A

0001 本发明属于医药技术领域，公开了筛选野生型α‑突触核蛋白聚集抑制剂和纤维解聚剂的方法和试剂盒及其应用。本发明以振荡温育法诱导重组人源野生型α‑突触核蛋白单体聚集，通过在聚集起始/形成纤维后与待测物质共同孵育，通过硫黄素‑T(ThT)荧光反应检测溶液中野生型α‑突触核蛋白聚集形成的β‑折叠的含量变化，由荧光值大小反映溶液中野生型α‑突触核蛋白的聚集程度，达到筛选抑制野生型α‑突触核蛋白聚集和促进野生型α‑突触核蛋白纤维解聚活性物质的目的，有益于发现靶向野生型α‑突触核蛋白聚集的先导物。

银杏酮酯中的碟豆素在改善神经炎症类认知障碍上的应用

Resumen de: CN122911999A

本发明涉及神经炎症下的认知障碍疾病技术领域，具体地说是银杏酮酯中的碟豆素在改善神经炎症类认知障碍上的应用。采用如下步骤：S1，通过分子对接筛选银杏酮酯入脑成分中可能作用于NKAα1的活性单体，并通过CETSA验证其与NKAα1的直接结合能力；S2，在LPS+ATP诱导的小胶质细胞炎症模型中，系统评估该单体对NKAα1内吞、NKAα1‑P2X7R相互作用、P2X7R介导电流及K⁺外流、以及NLRP3炎症小体激活的调控作用；S3，通过整体动物水平实验进一步探讨碟豆素改善PScDKO小鼠认知障碍的以及对NKAα1‑P2X7‑NLRP3信号轴的调控作用。同现有技术相比，分子对接结果表明银杏酮酯入脑成分碟豆素和水仙苷与NKAα1具有较好的结合能力；碟豆素和水仙苷在实验浓度范围内对BV2细胞活力无明显影响，并能抑制LPS+ATP诱导的炎症因子产生。

用于识别轻度认知障碍的生物标志物及其应用

Resumen de: CN122922398A

本发明涉及生物医药领域，具体涉及用于识别轻度认知障碍的生物标志物及其应用。该生物标志物，包括S‑腺苷同型半胱氨酸、黄体酮、溶血磷脂LPE 22:1、丙酸、β‑m‑羟基苯基‑羟基丙酸、雌二醇、17α‑羟孕酮、鞘磷脂SM 44:4、L‑哌啶酸、乙醇酸、雄烯二酮、L‑赖氨酸等中的至少一种。通过利用本发明实施例的生物标志物，实现了高灵敏度、高准确度的MCI检测方法，不仅在性能上显著提升了现有技术的检测能力，还大幅降低了检测的成本和操作的复杂性，对认知功能障碍的早期诊断具有重要的临床应用价值。

Method of nociceptor differentiation of human embryonic stem cells and uses thereof

Resumen de: AU2026237984A1

The present invention relates to the field of stem cell biology, in particular the linage specific differentiation of pluripotent or multipotent stem cells, which can include, but is not limited to, human embryonic stem cells (hESC), human induced pluripotent stem cells (hiPSC), somatic stem cells, cancer stem cells, or any other cell capable of lineage specific differentiation. Specifically described are methods to direct the lineage specific differentiation of hESC and/or hiPSC to nociceptors (i.e. nociceptor cells) using novel culture conditions. The nociceptors made using the methods of the present invention are further contemplated for various uses including, but limited to, use in in vitro drug discovery assays, pain research, and as a therapeutic to reverse disease of, or damage to, the peripheral nervous system (PNS). Further, compositions and methods are provided for producing melanocytes from human pluripotent stem cells for use in disease modeling. ep e p

PERSONALIZED SYNTHETIC BIOMARKER PANELS

Resumen de: US20260317833A1

Methods and systems for detecting disease using personalized synthetic biomarkers. Subject-specific molecular data, including one or more of genomic, epigenomic, transcriptomic, proteomic, or metabolomic data, are analyzed to identify disease-associated biological activities. Based on these activities, a set of synthetic biomarkers is designed for the subject, wherein each biomarker is configured to generate a detectable signal in response to a target biological process. The synthetic biomarkers are administered to the subject or contacted with a biological sample, and resulting signals are detected using analytical assays. Detection of the signals enables identification, monitoring, or assessment of disease presence, progression, or recurrence. In certain embodiments, the methods are applied to cancer, including minimal residual disease (MRD) detection, and may incorporate longitudinal monitoring and adaptive updating of biomarker panels based on changes in subject-specific molecular profiles.

SINGLE CELL SUPER-RESOLUTION PROTEOMICS

Resumen de: US20260318900A1

0000 Disclosed are methods for full morphological labeling of individual neurons from any species or cell type for subsequent cell-delineated protein analysis. These methods, which combines patch-clamp electrophysiology with epitope-preserving magnified analysis of proteome (eMAP), additionally allow for correlation of physiological properties with subcellular protein expression.

METHODS FOR TREATING INTRACRANIAL HEMORRHAGE AND ASSESSING EFFICACY

Resumen de: US20260315577A1

0000 The present disclosure relates to compositions and methods useful for assessing the hemostatic efficacy in a patient having suffered from intracranial hemorrhage while undergoing an anticoagulation treatment with a factor Xa (fXa) inhibitor. The method can include administering to the patient a fXa derivative that has reduced catalytic activity as compared to the wild-type fXa protein, is capable of binding to the factor Xa inhibitor and cannot assemble into a prothrombinase complex; obtaining a blood sample from the patient following the administration; and measuring an anti-fXa activity in the sample, wherein the anti-fXa activity reflects the hemostatic efficacy in the patient. Once the assessment is made, suitable medical interventions can be implemented.

METHOD FOR QUANTIFYING ERGOTHIONEINE

Resumen de: WO2026216120A1

The present disclosure can provide a simple and accurate method for quantifying ergothioneine in a sample containing globin protein. The present disclosure provides a method for quantifying ergothioneine in a collected sample, the method including: (A) a step for heating the sample; (B) a step for mixing the heated sample with trichloroacetic acid; and (C) a step for subjecting the sample obtained in step (B) to a quantification operation.

METHOD FOR DIAGNOSING AMYLOID DISEASES

Resumen de: AU2025249144A1

The present disclosure relates in some aspects to methods of labeling a detection reagent and uses thereof for detecting and diagnosing types of amyloid-related diseases. Also provided herein are methods of treatment comprising selecting a treatment based upon a particular type of amyloid disease.

METHOD TO DETERMINE THE EFFICACY OF A NEURODEGENERATIVE DISEASE TREATMENT

Resumen de: US20260318926A1

The present invention refers to the use of a biomarker for measuring the efficacy or effectiveness of treatments for neurodegenerative diseases, in particular, for Alzheimer's disease.

METHODS AND PRODUCTS FOR ASSESSING AUTOPHAGIC FLUX

Resumen de: AU2025232447A1

The present invention relates to methods and products for assessing autophagic flux, and more specifically provides a biochemical functional measure used to quantify autophagic flux in sub-populations of blood cells. The present invention also provides lysosomal system markers for use in the methods described herein, systems for assessing autophagic flux, methods of identifying markers indicative of autophagic flux, and methods of treating subjects found to be suffering from, or susceptible to, a disease, condition or state associated with autophagic flux dysfunction using the methods described herein.

Systems, Compositions, and Methods to Control the Integrated Stress Response

Resumen de: US20260317734A1

0000 Many embodiments are directed to systems, compositions, and methods to control the ISR. Numerous embodiments utilize optogenetic control to control the ISR. Optogenetic control can be provided by an engineered ISR kinase that can dynamically stimulate the ISR pathway. Using optogenetic control, many embodiments enable the selective activation of a single kinase of the ISR pathway without inducing real molecular damage, greatly reducing the combinatorial complexity of the signals that are turned on by real stressors. By changing the intensity of light stimulation, various embodiments can tune the fraction of optogenetic proteins in the activated state, thereby precisely altering the perceived intensity. Additionally, precisely defined input dynamics can be delivered by toggling lights between on and off positions. Many embodiments are scalable and/or capable of high-throughput delivery, allowing for precise dissections of the ISR pathway.

ANTI-IL1RAP ANTIBODIES

Resumen de: US20260317434A1

The present invention relates to antibodies or antigen-binding fragments thereof with binding specificity for interleukin-1 receptor accessory protein (IL1RAP). Furthermore, it relates to a polynucleotide encoding said antibodies, a vector comprising said polynucleotide and a recombinant host cell comprising said polynucleotide or said vector. Further, it relates to a method for producing said antibodies or antigen-binding fragments. Further, it relates to a composition comprising said antibodies or antigen-binding fragments, said polynucleotide, said vector and/or said host cell. Further, it relates to said antibodies or antigen-binding fragments, said polynucleotide, said vector, said host cell and/or said composition for use in medicine and/or for use in the prevention and/or treatment and/or alleviation and/or detection and/or diagnosis of a disease or disorder susceptible to treatment with an inhibitor of IL-1α, IL-1β, IL-33, IL-36α, IL-36β and/or IL-36γ signaling, optionally wherein the disease or disorder is associated with cells expressing IL1RAP.

METHODS OF DIAGNOSING AND TREATING MOOD AND PSYCHOTIC DISORDERS USING LYMPHOCYTE BIOMARKERS

Resumen de: AU2025231883A1

Blood-based biomarkers involving evaluation of membrane protein clustering (MPC) on peripherally circulating lymphocytes can identify individuals experiencing depression, schizophrenia, or bipolar disorder, while differentiating those that will respond to treatment from those that will not respond to treatment within the depressed populations. These markers can help diagnose and treat depression, schizophrenia, or bipolar disorder. Further, this diagnostic tool can identify individuals with treatment-resistant depression earlier. The disclosed automated method improves the throughput of blood-based biomarkers and can be standardized across multiple sites of blood collection/analysis. The automated approach performs similarly to human scorers for each method of blood smear collection in accurately obtaining cluster size means for each sample.

METHODS AND COMPOSITIONS FOR MEASURING AND MANAGING OXIDATIVE STRESS LEVELS

Resumen de: AU2025231935A1

Provided herein are methods for providing personalized antioxidant supplement blend for an individual subject based on the levels of antioxidant biomarkers, prooxidant biomarkers, and genetic statuses. The antioxidant supplement blend includes suggestions for one or more of diet, supplements, and/or life style changes for the individual.

DETECTION OF BIOMARKERS ON VESICLES FOR THE DIAGNOSIS AND PROGNOSIS OF DISEASES AND DISORDERS

Resumen de: US20260318925A1

Methods are disclosed that comprise providing a biological sample comprising extracellular vesicles, wherein the biological sample further comprises at least one extracellular vesicle biomarker and at least one cytosolic protein, cytokine, or secreted disease biomarker; contacting a solid support comprising capture agents associated therewith with the biological sample under conditions wherein the capture agents selectively bind to the at least one extracellular biomarker on the vesicles, thereby capturing said vesicles having the at least one extracellular vesicle biomarker on the solid support; separating the solid support from the biological sample; detecting a level of the at least one cytosolic protein, cytokine or secreted disease biomarker on the vesicles captured on the solid support using a detection agent that selectively binds to the at least one cytosolic protein, cytokine or secreted disease biomarker, wherein the vesicles are not lysed or permeabilized; detecting a level of the at least one extracellular vesicle biomarker on the vesicles; and determining a level of risk or presence of a neurological disorder or neurodegenerative disease based on the level of the at least one cytosolic protein, cytokine, or secreted disease biomarker in relation to the level of the at least one extracellular vesicle biomarker.

DETERMINING A HEALTH-RELATED CONDITION BY SELECTIVELY PERFORMING NUCLEIC ACID SEQUENCING IN RESPONSE TO A SCREENING TEST

Resumen de: US20260321424A1

Techniques for identifying a health-related condition based on a protein-based analysis, and optionally based on a nucleic acid sequencing-based analysis are described. In an example method, protein data of a sample obtained from the subject is identified. The sequence read data is indicative of proteins in the sample. The example method further comprises determining a protein score based on the protein data, and determining, based on the protein score, whether to determine a genomic score indicative of sequences of nucleic acid molecules in the sample. In the example method, input features are generated based on the protein score and/or the genomic score and classifying, using a classifier, the health-related condition of the subject based on the input features.

AGENTS AND METHODS FOR TREATING BENIGN PROSTATIC HYPERPLASIA

Resumen de: WO2026217989A1

Provided herein are methods of treating a subject having benign prostatic hyperplasia that include, for example, identifying a subject having a white blood cell that has an elevated level of methylation of SRD5A2 as compared to a reference level; and administering to the identified subject a first therapy such as a combination therapy comprising a therapeutically effective amount of a 5-alpha reductase inhibitor and a stroma-niched signaling therapeutic.

SALIVARY ENDOTOXIN DETECTION USING COMBINED MONO/POLYCLONAL ANTIBODY-BASED SANDWICH-TYPE LATERAL FLOW IMMUNOASSAY DEVICE

Resumen de: US20260318911A1

0000 A lateral flow assay device for detecting the presence of, or quantifying an amount or concentration of, analyte in a sample. The device includes (1) a conjugate region including a binding reagent coupled to a signal-generating particle, wherein the binding reagent comprises a first antibody configured to bind lipopolysaccharide, and wherein the binding reagent is mobile relative to the device, and (2) an analytical membrane in fluid communication with the conjugate region, the analytical membrane comprising a test region and a control region. The test region includes an immobilized capture reagent configured to capture a complex including the analyte and the binding reagent, wherein the immobilized capture reagent is a second antibody. The control region includes a control component configured to capture the binding reagent coupled to the signal-generating particle.

PREDICTION OF CAR NEUROTOXICITY USING NETWORK BIOSIGNATURES

Nº publicación: WO2026218003A2 15/10/2026

Solicitante:

SEATTLE CHILDRENS HOSPITAL D/B/A SEATTLE CHILDRENS RESEARCH INST [US]
SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE

Resumen de: WO2026218003A2

Provided are methods and compositions related to toxicity associated with administration of cell therapy for the treatment of diseases or conditions, e.g., cancer, including methods for use in predicting and treating toxicity. In some embodiments, the toxicity is a neurotoxicity or cytokine release syndrome (CRS), such as severe neurotoxicity or severe CRS. The methods generally involve determining a biosignature comprising of a differential modulation of one or more protein-interactions in a CAR-T cell to be administered relative to a reference standard. In some embodiments, the methods further involve administering an agent or therapy for treating, ameliorating, preventing, delaying and/or attenuating the development of the toxicity, such as neurotoxicity or CRS, such as severe neurotoxicity or severe CRS.